Elevation Oncology (NASDAQ:ELEV – Get Rating) and Acumen Pharmaceuticals (NASDAQ:ABOS – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability.
This is a summary of recent recommendations and price targets for Elevation Oncology and Acumen Pharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Elevation Oncology currently has a consensus price target of $4.50, indicating a potential upside of 76.47%. Acumen Pharmaceuticals has a consensus price target of $17.67, indicating a potential upside of 356.50%. Given Acumen Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Acumen Pharmaceuticals is more favorable than Elevation Oncology.
Volatility and Risk
Institutional and Insider Ownership
68.0% of Elevation Oncology shares are held by institutional investors. Comparatively, 67.9% of Acumen Pharmaceuticals shares are held by institutional investors. 17.0% of Elevation Oncology shares are held by insiders. Comparatively, 4.7% of Acumen Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This table compares Elevation Oncology and Acumen Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Elevation Oncology and Acumen Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Elevation Oncology||N/A||N/A||-$95.08 million||($7.36)||-0.35|
|Acumen Pharmaceuticals||$1.44 million||108.84||-$100.61 million||N/A||N/A|
Elevation Oncology has higher earnings, but lower revenue than Acumen Pharmaceuticals.
Acumen Pharmaceuticals beats Elevation Oncology on 6 of the 10 factors compared between the two stocks.
About Elevation Oncology
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
About Acumen Pharmaceuticals
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Receive News & Ratings for Elevation Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevation Oncology and related companies with MarketBeat.com's FREE daily email newsletter.